Janux Therapeutics (JANX) Receivables - Other (2023 - 2026)

Janux Therapeutics (JANX) has 4 years of Receivables - Other data on file, last reported at $7.5 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $7.5 million, up 33.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 million (up 33.63% YoY), and the FY2025 annual result was $6.4 million, up 19.46% from the prior year.
• Receivables - Other rose to $7.5 million in Q1 2026 per JANX's latest filing, from $6.4 million in the prior quarter.
• Over five years, Receivables - Other peaked at $7.5 million in Q1 2026 and troughed at $2.2 million in Q4 2023.
• A 4-year average of $5.2 million and a median of $5.5 million in 2024 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other surged 149.01% in 2024, then gained 19.46% in 2025.
• A 4-year view of Receivables - Other shows it stood at $2.2 million in 2023, then surged by 149.01% to $5.4 million in 2024, then advanced by 19.46% to $6.4 million in 2025, then climbed by 16.1% to $7.5 million in 2026.
• Business Quant data shows JANX's Receivables - Other at $7.5 million in Q1 2026, $6.4 million in Q4 2025, and $6.3 million in Q3 2025.